GlassScriptPhysician profile
Traci Dawn Knight
NPI 1306802822
$948.45
in general payments reported to CMS, 2019-2025
20 companies · $41.16 in 2025
The $41.16 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2023: $551 · 2024: $194 · 2025: $41.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $258.97 | 2023-2024 | |
| Lilly USA, LLC | $175.81 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $84.01 | 2021-2024 | Rexulti |
| Pfizer INC. | $58.10 | 2023 | |
| Xeris Pharmaceuticals, INC. | $47.56 | 2023 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $40.64 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.46 | 2024-2025 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $30.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.92 | 2025 | Caplyta |
| Novo Nordisk INC | $21.54 | 2024 | |
| Redhill Biopharma INC. | $21.50 | 2021 | |
| Dexcom, INC. | $21.43 | 2023 | Dexcom G6 Transmitter |
| Baxter Healthcare | $20.47 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Idorsia Pharmaceuticals US INC | $19.55 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $19.02 | 2023 | Trelegy Ellipta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2023 | Jardiance, Tradjenta |
| Vanda Pharmaceuticals INC. | $14.78 | 2021 | |
| Shield Therapeutics INC | $14.21 | 2023 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.